Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing

M Kocken1,2, J Berkhof3, FJ van Kemenade3, JA Louwers2, A Zaal2,4, MAE Nobbenhuis2,5, G Kenter6, PJF Snijders2, CJLM Meijer2 and TJM Helmerhorst*1,1

1Department of Obstetrics and Gynaecology, Erasmus MC University Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands; 2Department of Pathology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 3Department of Epidemiology and Biostatistics, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 4University Medical Centre Utrecht, Division of Woman and Baby, Gynaecological Oncology, PO Box 85500, 3508 GA Utrecht, The Netherlands; 5Department of Gynaecological Oncology, The Royal Marsden Hospital, Fulham Road, SW3 6JJ London, UK; 6Department of Obstetrics and Gynaecology, Centre Gynaecological Oncology Amsterdam (AMC, NKI-AVL, VUmc), VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands

BACKGROUND: Many studies have examined the short-term value of high-risk human papillomavirus (hrHPV) testing in predicting cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer (CIN3+). This study focuses on long-term CIN3+ risk after initial wait and see policy.

METHODS: A total of 342 women with abnormal cytology of borderline/mild dyskaryosis (BMD) or worse (> BMD), included between 1990 and 1992, were followed-up by cytology and hrHPV testing until 1996 and monitored by cytology thereafter. Primary endpoint was cumulative CIN3+ risk by December 2009.

RESULTS: Women with BMD had a 5-year CIN3+ risk of 22.5% (95% confidence interval (CI) 17.0–29.1) and of 0.7% (0.1–4.5) in the subsequent 5 years. High-risk human papillomavirus-negative women with BMD had a 5-year risk of < 0.01% (95% CI 0.0–5.1) and of < 0.01% (0.0–5.7) in the following 5 years, while for hrHPV-positive women these risks were 37.5% (29.0–46.9) and 1.6% (0.2–9.5), respectively. Women with > BMD had a 5-year risk of 45.1% (36.4–54.1) and of 3.5% (0.9–12.2) in the subsequent 5 years. High-risk human papillomavirus-negative women with > BMD had a 5-year risk of 7.3% (2.0–23.6) and hrHPV-positive women of 56.6% (46.4–66.3).

CONCLUSION: Women with BMD have an elevated CIN3+ risk for 5 years only; afterwards their risk is similar to the general population. High-risk human papillomavirus-negative women with BMD may return to regular screening directly. All other women with > BMD should be referred for additional testing and/or colposcopy.

Keywords: cervical cytology; human papillomavirus; cervical intraepithelial neoplasia; triage; screening

The incidence of cervical cancer has been lowered by the implementation of population-based screening programmes in which women are screened by cytological testing (Gustafsson et al., 1997; van Ballegooijen and Hermens, 2000; Castle et al., 2007). However, the sensitivity of cytological testing for cervical intraepithelial neoplasia grade 3 or cervical cancer (CIN3+) is moderate and compensated for by repetitive screening (Manos et al., 1999; Arbyn et al., 2006). In the Netherlands, an abnormal cytological test result is detected in ~2–4% of all screened women (van Ballegooijen and Hermens, 2000; Bulk et al., 2004; Bulkmans et al., 2004). In most developed countries, women with minor cellular abnormalities of borderline and mild dyskaryosis (BMD) will be followed by cytology, and will be referred for colposcopy if the smear remains abnormal (van Ballegooijen and Hermens, 2000; Bulkmans et al., 2004, 2007). Women with moderate and severe abnormalities (> BMD) are referred for colposcopy (van Ballegooijen and Hermens, 2000; Bulkmans et al., 2004). However, a substantial proportion of women with abnormal cytology will regress or do not harbour clinically meaningful cervical disease and will therefore be unnecessarily retested or referred.

Infection with a high-risk type of human papillomavirus (hrHPV) is the causative agent in cervical cancer (Walboomers et al., 1999; Bosch et al., 2002). Molecular testing for hrHPV has a higher sensitivity than cytology to detect CIN3+ (Manos et al., 1999; Cuzick et al., 2003, 2008; Arbyn et al., 2004, 2006; Bulkmans et al., 2007; Mayrand et al., 2007). In women with abnormal cytology, studies focus on the additional value of hrHPV in triaging women with equivocal or mildly abnormal cytological test results in order to increase efficiency of patient management (i.e., referral for colposcopy) and to identify women with an increased risk for high-grade CIN. As most of these studies had a restricted follow-up of at maximum 6 years, little is known on risk profiles with longer periods of follow-up and the effect of hrHPV testing in those situations (Manos et al., 1999; Nobbenhuis et al., 1999; Cuzick et al., 2003; Arbyn et al., 2004; Bais et al., 2005; Bulk et al., 2007;
Safaeian et al, 2007; Castle et al, 2009; Rijkaart et al, 2009; Cotton et al, 2010; Katki et al, 2011; Kelly et al, 2011; Kitchener et al, 2011; Levi et al, 2011). Only few studies have reported about a follow-up period of over 10 years (Sherman et al, 2003; Khan et al, 2005; Schiffman et al, 2011).

In this study we followed a group of women who were diagnosed with an abnormal cytology result of ≥ BMD for a maximum of 19 years and evaluated their long-term cumulative risk of developing CIN3+. Also the value of hrHPV testing for risk assessment was established as well as the duration of follow-up needed for women with dyskaryosis.

MATERIALS AND METHODS

Study population

For this cohort study we followed-up women who had participated in a previous study that studied the association between the presence of hrHPV and the development of high-grade cervical lesions (Nobbenhuis et al, 1999). Detailed methods of recruitment and follow-up until 33 months after intake have been published previously (Nobbenhuis et al, 1999, 2001). In short, between June 1990 and December 1992, 353 women were referred to the colposcopic outpatient clinic (VU University medical centre, Amsterdam, The Netherlands) with an abnormal cervical cytology result of mild, moderate or severe dyskaryosis. Until December 1996 each participant had been monitored for cervical disease every 3–4 months by testing for hrHPV, cytology, and colposcopy. Three expert colposcopists assessed serial colpophotographs and gave a consensus impression of the lesion. Only when they suspected a CIN3 lesion covering three or more cervical quadrants, or when a cervical smear result suspect of cervical cancer was found, a biopsy had been taken. At the end of the study in December 1996, all women had a colposcopic examination with mandatory biopsy (median 36 months, range 1–75). Women identified with high-grade disease (CIN2+) were treated according to Dutch guidelines. In Figure 1 follow-up procedures are depicted in a flowchart.

Procedures

Cytology results were originally reported using a classification that predated the currently used classification; therefore, all cytological referral slides were retrieved from the archives for blind review by an expert gynaeoco-pathologist (FvK). Dotted slides were scored and dichotomised into (≤) BMD, or > BMD. Women of whom no referral slide could be retrieved were excluded from this study.

Between December 1996 and December 2009 all women were monitored by cytological population-based screening once every 5 years. Interim-colposcopies were performed according to the national guidelines (NVOG, 2004). To complete the data obtained from routine screening, we invited all women to visit the outpatient clinic (VU University medical centre) for additional cytology and hrHPV testing during 2009 (Figure 1). If travel distance was a limitation to participate, women were offered the possibility of performing a hrHPV test at home by self-sampling. These test results are similar to those acquired by a physician (Bais et al, 2007; Petignat et al, 2007). Women who had had a hysterectomy were censored at the date of hysterectomy.

Two cervical specimens were obtained from women who visited the outpatient clinic (Cervex-brush, Rovers Medical Devices, Oss, The Netherlands). The first specimen was collected in a liquid-based cytology medium (Surepath, Tripath Imaging, Burlington, NC, USA), cytologically examined, and classified according to the CISOE-A classification, which is easily translatable into the Bethesda 2001 classification (Bulk et al, 2004). The second specimen was stored in Universal Collection Medium (Qiagen Corporation, Gaithersburg, MD, USA) for hrHPV testing. Women who self-sampled returned their cervicovaginal specimen for hrHPV testing by mail. All hrHPV samples were tested with the clinically validated GP5+/6+ PCR with enzyme-immunoassay read-out using a cocktail probe for 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 58, 59, 66 and 68), according to established protocols (van den Brule et al, 2002; Snijders et al, 2005). The PCR products of hrHPV-positive women were subsequently genotyped by reverse line blot hybridisation. Samples that were negative for any specific probe in this reverse hybridisation assay were considered positive for uncharacterised subtypes or variants (hrHPV X).

A standard colposcopic assessment was performed when a cytological test was abnormal at the threshold of borderline dyskaryosis, or when the hrHPV test was positive (Figure 1). Biopsies were taken of all suspect lesions. Histological specimens were graded as CIN0 (no dysplasia), CIN1, CIN2, CIN3, adenocarcinoma in situ (AIS) or invasive cancer (Wright, 1995) and classified according to the highest abnormality found in biopsy or treatment specimen. Women who developed CIN2+ were treated according to present guidelines but were censored at the time of treatment.

In December 2009, the hospital database and the Netherlands nationwide network and registry of histopathology and cytopathology (PALGA; Bunnik, The Netherlands) were reviewed for all women, irrespective of attendance, to ascertain details of any additional relevant events and procedures. Ethical approval was obtained from the Ethics Board of the VU University medical centre. All women who attended the outpatient clinic or participated by self-sampling provided additional signed informed consent. The study is registered in the Dutch trial register (NTR1470).

Statistical methods

In order to report long-term CIN risks in women with dyskaryosis, this study was designed as a follow-up of an observational cohort (Nobbenhuis et al, 1999).

As the original study was designed such that no interference with natural history would occur; a biopsy had only been taken when a colposcopic impression of CIN3 covering three or more cervical quadrants was present, or when a cytology result was suspect of cancer. As a consequence, the exact time at which CIN3+ lesions had developed was difficult to assess. We have calculated the 5-year, 10-year and overall risks until detection of CIN3+ using different approaches. In the first approach, we equalled the event time to the time of the first abnormal cytological result of moderate dyskaryosis or worse. In the second approach, the event time was equalled to the time of histological diagnosis. As the difference between the risks of these approaches were minimal (data not shown), we applied the second approach in further analyses. In women without an event, data were right-censored at the date of the last registered test.

The primary endpoint was the cumulative risk of CIN3+. We repeated the calculations with CIN2+ as secondary endpoint because treatment of CIN2 is common practice in most western countries. Both CIN3+ and CIN2+ included cases of AIS, adenocarcinoma (AC) and squamous cell carcinoma (SCC).

The cumulative CIN3+ risk was estimated by Kaplan–Meier analysis for the total group as well as for subgroups of different cytological and hrHPV test results at time of referral. In addition we repeated the calculations after dichotomising in younger (<30 years) and older (≥30 years) women. Differences in cumulative risk curves between subgroups were assessed by log-rank tests.

For women who did not develop high-grade CIN within 6 months after inclusion, we reset the time at 6 months to 0 to estimate the value of retesting with cytology, hrHPV or both after 6 months and the risk of persistent hrHPV infection (log-rank tests). For women who had not developed high-grade CIN at 5 years after
inclusion, time was reset from 5 years to 0 to estimate the CIN3+ risk from 5 years onwards.

By Cox regression we calculated CIN hazard ratios and 95% confidence intervals (CIs) to compare different test result combinations. Overall cumulative risks were calculated for different hrHPV genotypes to determine whether genotyping has additional value in the follow-up of women with abnormal cytology, focusing on HPV16. All calculations were performed using SPSS (Version 17.0, SPSS Inc, Chicago, IL, USA). All tests were two-sided and the level of significance was set at 0.05.

RESULTS

Of the original 353 women, 11 (3.1%) were excluded as no referral slide could be retrieved for review. For the remaining 342 women (median age 31 years, range 17–54) maximum follow-up depended on accrual date and ranged from 17.0 to 19.5 years. The total number of women years in our study was 3152. Overall censoring percentages were 13.2% (45 out of 342) at 5 years, 21.6% (74 out of 342) at 10 years and 36.5% (125 out of 342) at 15 years after detection of an abnormal cytological test result. During follow-up 4 women died of unrelated disease, 6 moved abroad, and 23 had a hysterectomy. None of the women had received prophylactic hrHPV vaccination.

During follow-up 105 (30.7%) CIN3+ cases were identified. Three were invasive cancers, of which two were SCC and one AC; two were AIS and 100 CIN3. Cervical intraepithelial neoplasia grade 2 was diagnosed in another 36 women. The cumulative risk curve of developing CIN3+ after an abnormal cytological test result in our cohort is shown in Figure 2. The 5-year CIN3+ risk was 31.1% (95% CI 26.1–36.6) and the risk in the next 5 years was 1.6% (0.5–4.9). Of all CIN3+, 96.2% (101 out of 105) were detected within 5 years of follow-up.

Figure 1  Flowchart of follow-up procedures. 1 Referral for colposcopy when once a cytology result of >BMD or when twice a result of BMD is detected. Abbreviations: BMD, borderline or mild dyskaryosis; hrHPV, high-risk human papillomavirus; CIN, cervical intraepithelial neoplasia.
Table 1 shows the 5- and 10-year risks of developing CIN3+ in 227 hrHPV-positive women (66.4%) and 115 hrHPV-negative women (33.6%). Only 3 (2.9%) of 105 CIN3+ lesions were found in women who were hrHPV negative at baseline. These were all CIN3 lesions. High-risk human papillomavirus-negative women had a 5-year CIN3+ risk of 1.9% (95% CI 0.5–7.0) and a risk of 1.1% (0.2–6.4) in the next 5 years. These risks were 45.1% (95% CI 38.4–52.0) and 2.1% (0.5–7.8), respectively, in hrHPV-positive women. Of the hrHPV-positive women 84.6% (192 out of 227) were infected with a single hrHPV type, 31 (13.7%) had a double infection and four (1.8%) were infected with three or more hrHPV types. All women who developed AIS or invasive cancer had only one hrHPV type: both SCC and one AIS contained HPV16, the AC harboured HPV18, and one AIS was positive for HPV45. In 93.3% (98 out of 105) of CIN3+ cases, the same hrHPV type was present both in the lesion and at the baseline, including both AIS, the AC and one SCC. Of one SCC, no hrHPV typing information was available.

The most prevalent type was HPV16 (105 out of 227, 46.3%), followed by HPV31 (29 out of 227, 12.8%), HPV18 (22 out of 227, 9.7%) and HPV33 (18 out of 227, 7.9%). The CIN3+ risk of women infected with HPV16 was higher than that of women infected with other hrHPV types (Wald statistic 8.85, P = 0.009).

The 5-year risk in HPV16-positive women was 56.5% (95% CI 46.5–66.0) and this was 36.5% (27.9–46.1) in nonHPV16-positive women. The risks in the subsequent 5 years were 0.01% (95% CI 0.0–10.7) and 3.4% (0.8–12.2), respectively. After stratification in two age categories, we found that in younger women (<30 years), HPV16-positive women had a significantly higher CIN3+ risk than nonHPV16-positive women (Wald statistic 13.01, P = 0.003, Table 1). Their 5-year CIN3+ risks were 61.5% (95% CI 46.8–74.4) and 19.9% (10.6–34.3), respectively. In older women (≥30 years), we found no difference in CIN3+ risk between HPV16-positive women and nonHPV16-positive women (Wald statistic 0.08, P = 0.78). Their respective 5-year risks were 52.1% (95% CI 38.9–65.1) and 31.1% (39.1–63.0).

In women infected with hrHPV types other than HPV16, 18, 31, 33 and/or 45, the CIN3+ risk remained 24.4% (95% CI 14.7–37.7) in the first 5 years and was 2.9% (0.5–15.1) in the following 5 years. These risks were similar for both the age categories.

Women with transient hrHPV infections had a lower CIN3+ risk than women who had a persistent 6-month hrHPV infection (Wald statistic 17.3; P = 0.0003). The 5-year CIN3+ risk was 2.2% (95% CI 0.4–12.2) in women who cleared their infection and 56.0% (48.0–63.7) in women with a persistent infection. Within the

| Baseline | At risk | CIN3+ | Risk (%) | 5 Year | 95% CI | Risk (%) | 10 Year | 95% CI |
|----------|---------|-------|----------|--------|--------|----------|---------|--------|
| All women | 342     |       | 31.1     | 26.1–36.6 | 95% | 32.2 | 26.9–38.0 | 95% |
| HPV negative | 115     |       | 1.9      | 0.5–7.0 | 95% | 3.0 | 0.9–9.2 | 95% |
| HPV positive | 227     |       | 45.1     | 38.4–52.0 | 95% | 47.0 | 39.9–54.2 | 95% |
| HPV16 | 105     |       | 56.5     | 46.5–66.0 | 95% | 56.5 | 46.1–66.3 | 95% |
| NonHPV16 | 122     |       | 36.5     | 27.9–46.1 | 95% | 38.7 | 29.5–48.8 | 95% |
| NonHPV16, 18, 31, 33, 45 | 61     |       | 24.4     | 14.7–37.7 | 95% | 26.6 | 16.1–40.6 | 95% |
| Age < 30 years |       |       |          |        |        |          |        |
| HPV positive | 104     |       | 40.4     | 30.7–51.0 | 95% | 41.8 | 31.6–52.8 | 95% |
| HPV16 | 49     |       | 61.5     | 46.8–74.4 | 95% | 61.5 | 46.2–74.8 | 95% |
| NonHPV16 | 55     |       | 19.9     | 10.6–34.3 | 95% | 22.8 | 12.3–38.3 | 95% |
| Age ≥ 30 years |       |       |          |        |        |          |        |
| HPV positive | 123     |       | 51.5     | 42.5–60.4 | 95% | 51.5 | 42.1–60.8 | 95% |
| HPV16 | 56     |       | 52.1     | 38.9–65.1 | 95% | 52.1 | 38.3–65.5 | 95% |
| NonHPV16 | 67     |       | 51.1     | 39.1–63.0 | 95% | 51.1 | 38.5–63.6 | 95% |
| Clearance <6 months* | 50     |       | 2.2      | 0.4–12.2 | 95% | 2.2 | 0.3–13.1 | 95% |
| 6-Month persistence* | 166     |       | 56.0     | 45.0–63.7 | 95% | 57.5 | 49.2–65.4 | 95% |
| Persistence HPV16 | 77     |       | 67.2     | 55.8–76.9 | 95% | 67.2 | 55.4–77.2 | 95% |
| Persistence nonHPV16 | 89     |       | 45.8     | 35.1–56.9 | 95% | 48.9 | 37.6–60.4 | 95% |

Abbreviations: CIN3+ = cervical intraepithelial neoplasia grade 3 and cancer; CIN2+ = cervical intraepithelial neoplasia grade 2 and cancer; 95% CI = 95% confidence interval; hrHPV = high-risk human papillomavirus. *All hrHPV-negative women at baseline and all women with a follow-up of <6 months were excluded. 6-Month persistence: at baseline and at 6 months at least one detected hrHPV type is similar. Time to event is set equal to histological diagnosis of CIN3+ or CIN2+ lesion.
persistent group, the risk of developing CIN3+ was higher in women positive for HPV16 (67.2%, 95% CI 55.8–76.9) than in women in whom other hrHPV types persisted (45.8%, 35.1–56.9, Wald-statistic 4.73; \( P = 0.03 \)).

Women were divided into two groups according to referral cytology: 210 (61.4%) women had a smear of BMD and 132 (38.6%) a smear of > BMD. In both these groups the median of cytological screens between 1996 and 2009 was 3.0 (range 1–9; \( P = 0.71 \), Mann–Whitney).

### Table 2  Risk (%) of cytology and hr-HPV testing at baseline and at 6-month follow-up, stratified according to baseline cytology in BMD and > BMD

#### (A) Women with borderline and mild dyskaryosis

| Baseline | Follow-up (6 months)* | BMD At risk | CIN3+ | 5 Year | Risk (%) | 5 Year | Risk (%) | 10 Year | Risk (%) | 10 Year | Risk (%) |
|----------|-----------------------|-------------|-------|--------|----------|--------|----------|---------|----------|---------|----------|
| All      | 210                   | 22.5        | 17.0–29.1 | 23.1   | 17.4–30.4 | 31.0   | 25.0–37.8 | 33.0   | 26.6–40.1 | 38.7   | 28.1–50.5 |
| Cyto negativeb,c | 65                  | 4.9         | 1.6–13.8 | 4.9    | 1.6–14.3  | 12.5   | 6.4–22.9   | 12.5   | 6.3–23.4   | 12.5   | 6.4–22.9   |
| Cyto positiveb,d | 127                | 30.9        | 23.0–40.1 | 31.8   | 23.3–41.7 | 38.0   | 29.7–47.0 | 41.5   | 32.7–50.9   | 38.0   | 29.7–47.0 |
| HPV negative | 84                  | 0.0         | 0.0–5.1   | 0.0    | 0.0–5.7   | 9.9    | 5.1–18.5   | 11.2   | 5.8–20.5    | 5.6    | 1.5–18.5   |
| HPV negative | 37                  | 0.0         | 0.0–10.2  | 0.0    | 0.0–10.7  | 5.5    | 1.5–18.1   | 5.5    | 1.5–18.6    | 10.9   | 5.7–29.5   |
| HPV positive | 40                  | 0.0         | 0.0–10.7  | 0.0    | 0.0–12.5  | 10.9   | 4.3–25.1   | 13.7   | 5.7–29.5    | 10.4   | 5.1–20.1   |
| HPV negative | 70                  | 0.0         | 0.0–6.1   | 0.0    | 0.0–6.6   | 10.4   | 5.1–20.1   | 10.4   | 5.1–20.1    | 12.5   | 2.4–47.1   |
| HPV positive | 9                   | 0.0         | 0.0–4.34  | 0.0    | 0.0–4.34  | 25.0   | 2.4–47.1   | 25.0   | 6.6–61.1    | 5.6    | 1.5–18.5   |
| Double negative | 36                 | 0.0         | 0.0–10.4  | 0.0    | 0.0–11.0  | 13.4   | 6.2–24.6   | 13.4   | 7.5–30.1    | 13.4   | 6.2–24.6   |
| HPV negative | 48                  | 0.0         | 0.0–9.2   | 0.0    | 0.0–10.4  | 13.4   | 6.2–24.6   | 13.4   | 7.5–30.1    | 13.4   | 6.2–24.6   |

#### (B) Women with moderate and severe dyskaryosis

| Baseline | Follow-up (6 months)* | > BMD At risk | CIN3+ | 5 Year | Risk (%) | 5 Year | Risk (%) | 10 Year | Risk (%) | 10 Year | Risk (%) |
|----------|-----------------------|-------------|-------|--------|----------|--------|----------|---------|----------|---------|----------|
| All      | 132                   | 45.1        | 36.4–54.1 | 47.0   | 37.8–56.4 | 51.2   | 42.6–59.7 | 55.3   | 46.4–63.9 | 51.2   | 42.6–59.7 |
| Cyto negativeb | 21                  | 5.0         | 0.9–23.6  | 15.0   | 5.1–36.7  | 5.0    | 0.9–23.6  | 15.0   | 5.1–36.7    | 5.0    | 0.9–23.6  |
| Cyto positiveb | 98                   | 53.9        | 43.5–64.0 | 53.9   | 42.9–64.5 | 60.7   | 50.7–69.9 | 64.0   | 53.7–73.2   | 60.7   | 50.7–69.9 |
| HPV negative | 31                  | 7.3         | 2.0–23.6  | 11.2   | 3.4–31.0  | 16.9   | 7.4–34.2  | 24.2   | 11.6–43.6   | 24.2   | 11.6–43.6 |
| HPV negative | 10                  | 0.0         | 0.0–29.9  | 11.1   | 1.8–45.6  | 0.0    | 0.0–29.9  | 11.1   | 1.8–45.6    | 0.0    | 0.0–29.9  |
| HPV positive | 18                  | 13.5        | 3.7–39.1  | 13.5   | 3.0–44.3  | 29.4   | 13.3–53.1 | 36.5   | 16.9–61.9   | 29.4   | 13.3–53.1 |
| HPV positive | 30                  | 7.4         | 2.0–23.8  | 11.3   | 3.5–31.1  | 14.1   | 5.6–31.3  | 21.6   | 9.7–41.3    | 14.1   | 5.6–31.3  |
| HPV positive | 1                   | 0.0         | 0.0–9.99  | 11.1   | 1.8–45.6  | 0.0    | 0.0–9.99  | 11.1   | 1.8–45.6    | 0.0    | 0.0–9.99  |
| HPV negative | 10                  | 0.0         | 0.0–29.9  | 11.1   | 1.8–45.6  | 0.0    | 0.0–9.99  | 11.1   | 1.8–45.6    | 0.0    | 0.0–9.99  |
| HPV positivea | 21                  | 11.2        | 3.0–37.2  | 11.2   | 2.6–37.5  | 25.0   | 11.2–46.9 | 30.8   | 14.2–54.5   | 25.0   | 11.2–46.9 |

#### Abbreviations:
- CIN3+ = cervical intraepithelial neoplasia grade 3 and cancer; CIN2+ = cervical intraepithelial neoplasia grade 2, 3 and cancer; 95% CI = 95% confidence interval; HPV = human papillomavirus.
- All women with a follow-up of < 6 months were excluded.
- Cytology divided into negative (normal) and positive (borderline or mild dyskaryosis and worse).
- Including one adenocarcinoma in situ (AIS), including one squamous cell carcinoma (SCC), including one SCC, one adenocarcinoma, and one AIS. Time to event is set equal to histological diagnosis of CIN3+ lesion.

### Borderline and mild dyskaryosis

Forty-seven of 210 (22.4%) women with BMD developed CIN3+. Their 5-year CIN3+ risk was 22.5% (95% CI 17.0–29.1) and their risk in the subsequent 5 years was 0.7% (0.1–4.5; Table 2A). Immediate hr-HPV testing clearly stratified these women with regard to cumulative risk (Wald-statistic 11.08, \( P = 0.001 \), Figure 3A). A negative hr-HPV test result, present in 84 (40.0%) women, reduced the 5-year CIN3+ risk to 0.01%.
Clinical Studies

P cytology or hrHPV (Wald-statistic 8.51; hrHPV types different from HPV16, 18, 31, 33 and 45. risk remained 26.5% (95% CI 14.1–44.3) in women infected with other hrHPV types. The 5-year risk for women positive for HPV16 was similar to the risk for nonHPV16-positive women (Wald-statistic 1.01; P = 0.31). Thirty-one (23.5%) women tested hrHPV negative and had a 5-year CIN3 risk of 7.3% (95% CI 2.0–23.6) and of 4.2% (0.6–23.2) in the subsequent 5 years. Additional testing after 6 months with either cytology, hrHPV, or both did not further stratify the risk (Wald statistic 0.07, P = 0.80; 0.02, 0.90 and 0.009, 0.93, respectively). Also after age stratification no groups could be identified with a low enough risk to return to routine screening.

**Analyses with CIN2 as endpoint**

Results of analyses with CIN2 as endpoint were similar to those with CIN3 as endpoint (Tables 1 and 2). The 5-year CIN2 risk for women with abnormal cytology was 38.7% (95% CI 33.6–44.1) and this risk was 4.7% (2.4–9.0) between 5 and 10 years. Of all 141 CIN2 lesions, 124 (87.9%) were detected in women who were hrHPV positive at baseline. Their 5-year CIN2 risk was 52.3% (95% CI 45.7–58.8) and 6.1% (2.7–13.1) in the next 5 years. Human papillomavirus 16-positive women had a 5-year CIN2 risk (60.0%, 95% CI 50.2–69.1) similar to the risk in women infected with other hrHPV types (45.7%, 37.0–54.7, Wald-statistic 3.32; P = 0.07). Women who tested hrHPV negative at baseline had a 5-year risk of 11.8% (95% CI 7.0–19.2) and a risk of 3.3% (1.1–9.6) in the subsequent 5 years.

The 5-year CIN2 risk in women with BMD was 31.0% (95% CI 25.0–37.8), and their risk in the next 5 years was 3.0% (1.1–7.8). A negative hrHPV-test result at baseline reduced the 5-year risk to 9.9% (95% CI 5.1–18.5), whereas a positive test increased the risk to 44.9% (37.1–52.9). Human papillomavirus 16-positive women had a significantly higher risk than women infected with other hrHPV types (55.3%, 95% CI 41.8–68.1 vs 38.7, 28.1–50.5).

The CIN2 risk in women with >BMD was 51.2% (95% CI 42.6–59.7) in the first 5 years and 8.4% (3.5–18.8) in the next 5 years. A negative hrHPV test result reduced the 5-year risk to 16.9% (95% CI 7.4–34.2) and a positive hrHPV test result increased this risk to 61.4% (31.5–70.4%). Human papillomavirus 16 had a similar CIN2 risk as other hrHPV types in women with >BMD (Wald-statistic 0.01; P = 0.91).

**DISCUSSION**

This study describes the long-term cumulative risk of developing CIN3 after detection of abnormal cytology. For women with an abnormal smear (≥BMD) the 5-year CIN3 risk was 31.1% and the risk in the next 5 years was 1.6%. We stratified these risks according to referral cytology and found that both women with BMD and women with >BMD referral cytology had an increased risk of developing CIN3 within the first 5 years after detection. This risk was twice as high in women with >BMD compared with women with BMD (45% vs 22%). In the subsequent 5 years only for women with >BMD an increased risk (3.5%) remained, while for women referred with BMD this risk was with 0.7% similar to that of the general population (Bulkmans et al, 2004).

Immediate hrHPV testing stratified the CIN3 risk of women with an abnormal smear (≥BMD). Almost all CIN3 lesions (102 out of 105), including all invasive carcinomas, were found in women testing hrHPV positive. Almost half of all hrHPV-positive...
women were infected with HPV16; these women had a significantly higher CIN3+ risk than the women infected with other hrHPV types (Khan et al, 2005; Schiffman et al, 2005, 2011; Berkhof et al, 2006; Castle et al, 2009). This risk difference was only found in younger women (<30 years), while in older women (≥30 years) the risks between women positive for HPV16 and women positive for other hrHPV types were similar. This is in line with another study (Powell et al, 2011) that found that the mean age of women with HPV16-associated cancer was significantly lower than of non-HPV16-associated cancer. All CIN3+ in HPV16-positive women were identified within 5 years after detection of abnormal cytology, while lesions associated with other hrHPV types were also found in the 5 years hereafter. This suggests that HPV16 has its main oncogenic effect within a shorter timeframe and at a younger age than other hrHPV types (Safaeian et al, 2009; Powell et al, 2011).

The CIN3+ risk was lower in women who cleared the virus than in women with persistent hrHPV infections, with the highest risks for women with a persistent HPV16 infection (Schiffman et al, 2005; Kjaer et al, 2006; Naucler et al, 2007; Castle et al, 2009).

Women with BMD

In correspondence with another Dutch study (Berkhof et al, 2006), almost 25% of women with BMD developed CIN3+. The majority was diagnosed within the first 5 years, whereas in the subsequent 5-year period their CIN3+ risk was similar to that of the general population (Bulkmans et al, 2004; Castle et al, 2007). This implicates that women with BMD who did not develop CIN3+ within 5 years may return to routine screening. Other studies also found a negligible increase in high-grade CIN cases between 5 and 10 years after diagnosis of BMD cytology (Sherman et al, 2003; Khan et al, 2005; Schiffman et al, 2011).

Meta-analyses concerning women with BMD have found that immediate hrHPV testing better identifies women at risk of developing CIN3+ than repeat cytology after 6 months (Arbyn et al, 2004, 2006). Our study confirms these findings. Women with baseline BMD and normal cytology after 6 months (31%) had a 5-year risk of 5%, while this risk was <0.1% in women with BMD and a negative hrHPV test at baseline (46%). Therefore, we support the referral of hrHPV-negative women with BMD to routine screening (Castle et al, 2007; Safaeian et al, 2007; Rijken et al, 2009; Katki et al, 2011; Levi et al, 2011). In both these groups, the 5-year CIN2+ risk remained ~10%. After revision, all these lesions remained CIN2, and we believe most of them would regress over time. However, additional testing with either cytology or hrHPV after 6 months may be considered to minimise the risk of CIN2.

Women with BMD who tested hrHPV positive at baseline had a 5-year CIN3+ risk of almost 40% and are in need of additional testing and/or colposcopy (Manos et al, 1999; Bulkmans et al, 2004; Castle et al, 2007; Safaeian et al, 2007). Although hrHPV genotyping did identify HPV16-positive women to have the highest risk, the risk of women positive for other hrHPV types remained so high (28.8%) that colposcopic referral was required, leaving hrHPV genotyping without additional value.

Another strategy to identify women at risk for CIN3+ is hrHPV testing after 6 months, allowing viral clearance (Bais et al, 2005; Berkhof et al, 2005). In our study, almost half (99 out of 210) of the women with BMD tested hrHPV negative after 6 months. As none of them developed CIN3+, this confirms the usefulness of this alternative strategy. However, also with this strategy the 5-year CIN2+ risk in hrHPV-negative women remains 10%.

Women with >BMD

As almost half of the women with >BMD cytology developed a CIN3+ lesion, we support referring all women with >BMD to colposcopy (Bulkmans et al, 2004; Castle et al, 2007). Although immediate hrHPV testing did stratify the risk of developing CIN3+, no group was identified with a risk low enough to refrain from colposcopy. Therefore, we do not advocate hrHPV testing in this group.

Our study has several limitations. First, the initial study was designed such that no interference with natural history would occur and therefore had a ‘wait and see’ period to allow the development of real precursor lesions (CIN3), instead of transient lesions (CIN2). When CIN2+ lesions were detected women were treated, which is in contrast to another observational study (McCreedie et al, 2008). The waiting period is also an explanation for the later diagnosis of CIN3+ lesions in our study than found in other recent European studies in which the majority of disease was diagnosed within 12 months (Dillner et al, 2008).

Second, our study comprises a relatively small cohort of 342 women. Although the censoring percentage at 10 years was only 20%, just one event was diagnosed after 10 years of follow-up. Therefore, we describe the risks up to 10 years and presented 95% CI to assess all risks as precisely as possible, providing a general impression on the long-term CIN risk of women with an abnormal smear (≥BMD). Our results corroborate and extend the data of other (long-term) cohorts (Sherman et al, 2003; Kjaer et al, 2006; Bulk et al, 2007; Dillner et al, 2008; Katki et al, 2011; Kelly et al, 2011; Kitchener et al, 2011; Schiffman et al, 2011). As most CIN3+ were detected within 5 years of referral (Sherman et al, 2003), the presented overall 5- and 10-year CIN3+ risks are with 31.1% and 32.2% nearly similar. These risks were higher than reported previously by Dillner (6-year risk 19%) and Sherman (10-year risk 10.2%; 95% CI 7.6–12.9) (Sherman et al, 2003; Dillner et al, 2008). Possible explanations include differences in the study population, that is the relatively large proportion (39%) of women with >BMD, and the strict endpoint of biopsy taking in the initial study. Other studies often acted on less severe suspicions, thereby increasing the detected number of lower grade CIN lesions (Sherman et al, 2003; Cuzick et al, 2008; Schiffman et al, 2011).

A number of CIN2 lesions that would have been detected in countries with less conservative referral thresholds, such as the United States and the United Kingdom, will in the Netherlands have developed into CIN3+ lesions before detection. This explains the relatively higher number of CIN3+ lesions and the relatively lower number of CIN2 lesions.

Finally, the median age was relatively low. However, conclusions did not differ greatly after recalculating the risks for 196 women aged ≥30 years (data not shown).

In conclusion, our study confirms the increased CIN3+ risk in women with dyskaryosis. Bearing in mind the limitations of our study, we recommend the following: Women with BMD should receive additional hrHPV testing for risk assessment. HrHPV-negative women may be referred to routine screening as their 5-year CIN3+ risk is negligible. HrHPV-positive women should be referred for additional testing and/or colposcopy. When these women do not develop CIN3+ within 5 years, they also may be referred to population-based screening. Women with BMD should all be referred for colposcopy and as their CIN3+ risk is elevated for at least 10 years long-term monitoring is required.

ACKNOWLEDGEMENTS

This work was supported by the VU University medical centre, Amsterdam, The Netherlands; and the ErasmusMC University medical centre, Rotterdam, The Netherlands. We thank research staff and technicians of the unit of molecular pathology for HPV DNA testing and logistics, the cytotechnicians for cytological testing and logistics, and the information technology team of the Department of Pathology for their supportive work. We are also
grateful for the active cooperation of the team of the outpatient clinic of the Department of Obstetrics and Gynecology, all part of the VU University medical centre, Amsterdam, The Netherlands. In addition, we also thank all women who participated in our trial.

Conflict of interest

CJLM and PJFS have relationships with Self-screen and CJLM has a relationship with Qiagen that might have an interest in the submitted work in the previous 3 years. Their spouses, partners, or children have no financial relationships that may be relevant to the submitted work. The remaining authors declare no conflict of interest.

REFERENCES

Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J (2004) Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96: 280 – 293

Arbyn M, Sasienski P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J (2006) Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl 3): 78 – 89

Bais AG, Rebolj M, Snijders PJ, de Schipper FA, van der Meulen DA, Smit ME, van den Brule AJM, Meijer CJ (2007) Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 121: 361 – 367

Bais AG, van Kemenade FJ, Berkhof J, Van Ballegooijen M, Smit ME, van den Brule AJM, Meijer CJ (2006) Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 115: 268 – 275

Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244 – 265

Berkhof J, Bulkman NW, Berek JH, Rozenzaal L, Boeke AJ, Verheijen RH, Snijders PJ, Meijer CJ (2007) Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 121: 361 – 367

Berkhof J, de Brijnje MC, Zielinski GD, Bulkman NW, Rozenzaal L, Snijders PJ, Verheijen RH, Meijer CJ (2005) Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer 116: 122 – 129

Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, Babovic M, van Ballegooijen M, Helmerhorst TJ (2005) Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. J Int Cancer 120: 1505 – 1510

Kelly RS, Patnick J, Kitchener HC, Moss SM (2011) HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 105: 983 – 988

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072 – 1079

Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, Desai M, Mather J, Turner A, Moss S, Peto J (2011) A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: results from the ARTISTIC trial. Eur J Cancer 47: 864 – 871

Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC (2011) Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions. Cancer Cytopathol 119: 228 – 234

CJLM and TJMH were project leaders and designed the study. MK, JB, CJLM and TJMH drafted the manuscript. Patients were included by MK, JL and AZ. TJMH was clinical supervisor. MK and JB analysed the data; JB was responsible for data analyses. MK was responsible for data management and study coordination. MN was responsible for data management in the initial study. CJLM and PJFS were responsible for HPV DNA testing. CJLM and FJvK were responsible for cytological analyses. FJvK reviewed all referral cytology. GK was responsible for communication with gynaecologists. All authors critically reviewed the manuscript and approved the final version.

Author contributions

Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 339: b2569

Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M (2007) Risk assessment for guiding the prevention of cervical cancer. Am J Obstet Gynecol 197: 3561 – 3566

Cotton S, Sharp L, Little J, Cruickshank M, Seth R, Smart I, Duncan I, Harrild K, Neal K, Waugh N, Trial Of Management of B & Other Low-Risk Abnormal Smears G (2010) The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial. BJOG 117: 645 – 659

Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGooran E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Casiens P (2003) Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362: 1871 – 1876

Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, Ho L, Terry G, Casiens P, Soutter WP (2008) Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology results from the Rammersmith study. Int J Cancer 122: 2294 – 2300

Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler F, Lloberas V, Bjer J, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, Joint European Cohort S (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337: a1754

Gustafsson L, Ponten J, Zack M, Adami HO (1997) International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 8: 755 – 763

Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE (2011) Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12: 663 – 672

Kelly RS, Patnick J, Kitchener HC, Moss SM (2011) HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 105: 983 – 988

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072 – 1079

Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, Desai M, Mather J, Turner A, Moss S, Peto J (2011) A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 47: 864 – 871

Kjaer S, Hogdall E, Frederiksen K, Munk C, van den BA, Svare E, Meijer CJ (2004) POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 110: 94 – 101

Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC (2011) Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions. Cancer Cytopathol 119: 228 – 234

Clinical Studies
Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Bensley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA (1999) Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 281: 1605–1610

Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferencyz A, Ratnam S, Coutlee F, Franco EL (2007) Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357: 1579–1588

McCredie MR, Sharplees KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9: 425–434

Naquet P, Ryd W, Tornberg S, Strand A, Wedell G, Elfgen K, Radberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J (2007) Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357: 1589–1597

Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemert PD, Verheijen RH, Meijer CJ (2001) Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358: 1782–1783

Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Riise EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ (1999) Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354: 20–25

NVON (2004) National Guideline ‘Cervical Intraepithelial Neoplasia’, (in Dutch), http://www.oncoline.nl/cervicale-intra-epitheliale-neoplasie (accessed on 7 September 2011)

Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F (2007) Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 105: 530–535

Powell NG, Hibbits SJ, Boyde AM, Newcombe RG, Tristram AJ, Fieder AN (2011) The risk of cervical cancer associated with specific types of human papillomavirus: a case-control study in a UK population. Int J Cancer 128: 1676–1682

Rijkstra DC, Berkhof J, van Kemenade FJ, Rozendaal L, Verheijen RH, Bulk S, Herreelers ME, Verweij WM, Snijders PJ, Meijer CJ (2009) Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). Int J Cancer 126: 2175–2181

Safaeian M, Schiffman M, Gage J, Solomon D, Wheeler CM, Castle PE (2009) Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res 69: 3262–3266

Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P (2007) Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 109: 1325–1331

Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD (2011) A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 20: 1398–1409

Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Allaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337: 76–84

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M (2003) Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95: 46–52

Snijders PJ, van den Brule AJ, Jacobs MV, Pol RP, Meijer CJ (2005) HPV DNA detection and typing in cervical scrapes. Methods Mol Med 119: 101–114

van Ballegooijen M, Hermens R (2000) Cervical cancer screening in the Netherlands. Eur J Cancer 36: 2244–2246

van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schous LM, Meijer CJ, Snijders PJ (2002) GPS+6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 40: 779–787

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12–19

Wright TC (1995) Precancerous lesions of the cervix. In Blaustein’s Pathology of the Female Genital Tract, Kumar RJ (ed) pp, 248–57. Springer Verlag: New York

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.